Depot eröffnen. Abheben.

Bei unserem Broker finanzen.net ZERO handelst du alle deine Aktien ohne Ordergebühren (zzgl. Spreads). Sichere dir als Neukunde jetzt 1 Lufthansa-Aktie und 2 MSCI World Anteile gratis! (Code: START2026)

Es gelten die Teilnahmebedingungen.

Nicht mehr anzeigen

Apellis Pharmaceuticals Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

16,53 EUR +0,03 EUR +0,19 %

15:48:03

STU

19,01 USD +0,07 USD +0,37 %

15:57:59

BTT

Apellis Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.2,12 Mrd. EUR

KGV145,71Div. Rendite0,00%

WKNA2JAAW

ISINUS03753U1060

SymbolAPLS

Apellis Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

08.08.24PR NewswireSobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

29.09.23PR NewswireAPLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

21.09.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

WerbungApellis Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.09.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

09.09.23PR NewswireAPELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. ...

05.09.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

28.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

26.08.23PR NewswireAPELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. ...

18.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

16.08.23PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)

11.08.23PR NewswireAPLS SHAREHOLDER ALERT: Jakubowitz Law Reminds Apellis Shareholders of a Lead Plaintiff Deadline of October 2, 2023

10.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

10.08.23PR NewswireAPLS LAWSUIT ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

10.08.23PR NewswireROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

08.08.23PR NewswireAPLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. Shareholders

05.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

04.08.23PR NewswireROSEN, NATIONAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

25.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

19.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

Apellis Pharmaceuticals News

Apellis Pharmaceuticals News: auf dieser Seite finden Sie alle Apellis Pharmaceuticals News und Nachrichten zur Apellis Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Apellis Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Apellis Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.